Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

EP: 1.Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

EP: 2.CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer

EP: 3.Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer

EP: 4.Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

EP: 5.Clinical Perspectives: Use of CDK4/6i After CDK4/6i

EP: 6.The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

EP: 7.Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

EP: 8.Emerging Data of Additional SERDs in Metastatic Breast Cancer

EP: 9.CDK4/6 Inhibitors Plus Novel Agents for ER+/HER2–Advanced or mBC

EP: 10.Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

EP: 11.Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

EP: 12.Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

EP: 13.Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBC

EP: 14.ADCs: Recent Data of Dato-DXd from TROPION-Breast01

EP: 15.Impact of ADC Toxicities and Clinical Decision-Making for mBC

Now Viewing

EP: 16.Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

Video content above is prompted by the following:

1. Dr. Bardia to All Panelists: How do you choose amongst the therapeutic options if multiple molecular alterations are detected?
   1. Are there particular patient populations that are better suited to one therapy or class over aanother?
2. Dr. Bardia to All Panelists: What other potential advances are you excited about in the HR+/HER2–- breast cancerBC space?